English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

In countries with a high prevalence of the sickle cell trait (SCT), which is often determined by neonatal screening programs, a significant proportion of blood donors may be SCT carriers [1]. In Brazil, for example, where SCT prevalence ranges from 1.1% to 9.8% in the overall population [2], the trait is found in up to 2.48% of blood donors [3-7]. Because individuals with SCT are usually asymptomatic, many of them are unaware of their condition at the time of donation [1]. Considering the potential risks associated with SCT blood donation for both donor and recipient, particularly those with sickle cell disease [8], routine HbS screening in first-time blood donations is generally recommended [9].

A new insight into apheresis platelet donation by sickle cell trait carriers: evidences of safety and quality